A genomic variant of ALPK2 is associated with increased liver fibrosis risk in HIV/HCV coinfected women.
HIV coinfection is associated with more rapid liver fibrosis progression in hepatitis C (HCV) infection. Recently, much work has been done to improve outcomes of liver disease and to identify targets for pharmacological intervention in coinfected patients. In this study, we analyzed clinical data of...
Main Authors: | Alec T McIntosh, Renhuizi Wei, Jaeil Ahn, Brad E Aouizerat, Seble G Kassaye, Michael H Augenbraun, Jennifer C Price, Audrey L French, Stephen J Gange, Kathryn M Anastos, Radoslav Goldman |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0247277 |
Similar Items
-
Treatment of HBV–HCV coinfection
by: Rocío Torres Ibarra
Published: (2006-01-01) -
Treatment of HCV and HIV coinfection
by: J. Alberto Juárez Navarro
Published: (2006-01-01) -
Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter?
by: Autumn D Zuckerman, et al.
Published: (2019-01-01) -
HIV-HCV coinfection and liver cancer
by: Aluisio Segurado -
Immunological aspects of HCV/HIV coinfection
by: Nikolay Dmitrievich Yushchuk, et al.
Published: (2011-11-01)